Table 4.

Logistic regression analysis on risk factors for developing non-cardiogenic pulmonary hypertension during tyrosine kinase inhibitor treatment.

	Univariate analysis		Multivariate analysis
Factors	Odds ratio (95% CI)	P	Odds ratio (95% CI)	P
Old age (>60 y)	15.8 (2.0–127.4)	.01	12.3 (1.1–142.1)	.04
Gender, female	1.0 (0.3–3.7)	.97	—	—
Sokal score, high	1.7 (0.5–6.0)	.37	—	—
Hasford score, high	0.4 (0.1–1.5)	.18	—	—
Dasatinib treatment	4.9 (1.4–17.5)	.02	8.2 (1.3–50.6)	.03
Second or higher line TKI	1.1 (0.3–4.5)	.88	—	—
Long TKI treatment (>5 y)	0.7 (0.2–2.7)	.58	—	—
Diabetes mellitus	3.1 (0.9–11.6)	.10	—	—
Hypertension	5.6 (1.6–19.5)	.01	2.0 (0.2–16.6)	0.50
Chronic kidney disease	7.4 (2.1–26.1)	.002	1.6 (0.2–14.5)	0.70
Cardiopulmonary symptoms	45.2 (8.9–229.6)	.001	36.1 (5.3–247.3)	0.001

CI = confidence interval, TKI = tyrosine kinase inhibitor.